ak-104
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Oct 3, 2017 (NCT03261011)
Timeline
Indications
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
- CD27 antigenINHIBITOR
CD27 inhibitor
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06832917 | Phase 3 | Mar 31, 2025 | Shenzhen University |
| NCT06998394 | Phase 2 | Mar 12, 2025 | Zhengzhou University |
| NCT05430906 | Phase 2 | Jul 31, 2022 | Central South University |
| NCT04220307 | Phase 2 | Feb 10, 2020 | Akeso Pharmaceuticals, Inc., Sun Yat-Sen University |
| NCT03261011 | Phase 1 | Oct 3, 2017 | Akeso Pharmaceuticals, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2017 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Shenzhen University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Zhengzhou University | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1